Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM-336 in Relapsed/Refractory or Newly Diagnosed AL Amyloidosis
NCT06769555Withdrawn
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2025
- Primary completion
- Aug 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Open-label, single-arm trial of gamgertamig in amyloid light chain amyloidosis, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Hematologic response VGPR or better rate at 4 months and Adverse events and serious adverse events at 2 years. Planned start Jan 2025; status: withdrawn.
02
Drugs
gamgertamig
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT06769555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06769555.